Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Drug Class (Bronchodilators (Beta 2-Agonists, Anticholinergics, Theophyllines), Phosphodiesterase Type 4 Inhibitors, Steroids, and Others), by Route of Administration (Oral and Inhalation), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 17,510.15 Million in 2022 and is expected to exhibit a CAGR of 4.9% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Global chronic obstructive pulmonary disease (COPD) treatment market is expected to witness significant growth over the forecast period, owing to factors such as collaborations and partnerships, mergers and acquisitions, and product launches by the key players. Active involvement by market players to improve medication adherence in COPD patients, increasing awareness about the disease, and research and development by the key players is expected to drive the global chronic obstructive pulmonary disease (COPD) treatment market growth. In January 2019, ResMed Inc., a medical device company announced a complete launch of its portable oxygen concentrator, Mobi, in the U.S. for chronic obstructive pulmonary disease (COPD) or other chronic diseases. Adherium, a digital health platform company focusing on improving medication adherence and patient outcomes, launched the Hailie solution in the U.S., in 2018. The Hailie solution is designed to help patients achieve better adherence by providing people who live with asthma or chronic obstructive pulmonary disease (COPD) with the tools to manage their condition. Moreover, Adherium, and Vitalus Health, healthcare clinic collaborated to combine the benefits of Adherium’s Hailie solution, and Vitalus Health provider system in 2018. These factors are expected to drive global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period.
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the global chronic obstructive pulmonary disease (COPD) treatment market, owing to its possible association with the COVID-19 infection and increasing research and development and product approval for the chronic obstructive pulmonary disease treatment. For instance, according to an article published by the National Center for Biotechnology Information, a series of databases relevant to biotechnology and biomedicine, in November 2021, clinically important features of SARS-CoV-2 pathogenesis include, infection of cells via binding of the viral spike protein to angiotensin-converting enzyme 2 (ACE2) receptors, with cell entry requiring type 2 transmembrane serine protease to cleave ACE2 receptor and activate viral spike protein. Infection of nasal and bronchial epithelial cells and pneumocytes early in infection. Acceleration of viral replication and compromise of epithelial-endothelial barrier integrity in later stages, resulting in a dysregulated inflammatory response and a hypercoagulable state. Dysregulation of renin-angiotensin-aldosterone system, which may also contribute to infection-related tissue damage. The chronic obstructive pulmonary disease treatment was used initially in first COVID wave to treat the coronavirus infection.
Furthermore, in July 2020, AstraZeneca, a pharmaceutical company, received approval for Breztri Aerosphere from the U.S. Food and Drug Administration (FDA) on the basis of positive results from the Phase III ETHOS trial in which Breztri Aerosphere, a triple-combination therapy, showed a statistically significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies Bevespi Aerosphere (glycopyrrolate/formoterol fumarate) and PT009 (budesonide/formoterol fumarate). The approval was also supported by efficacy and safety data from the Phase III KRONOS trial.
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Key Developments
In June 2022, AstraZeneca, a pharmaceutical and biotechnology company, planned to build a manufacturing facility in Qingdao, China, to produce its Breztri aerosol inhalant Chronic Obstructive Pulmonary Disease (COPD) treatment, which was recently added to the country’s National Reimbursement Drug List.
In July 2022, Centenary Institute of Cancer Medicine and Cell Biology, Centenary Institute and the University of Technology Australia, had identified a new drug target for the treatment and prevention of chronic obstructive pulmonary disease (COPD), an inflammatory lung disease that causes airway blockage and that makes person difficult to breathe. In their new study, the researchers discovered elevated CMA1 levels in the lung tissues of patients with severe chronic obstructive pulmonary disease. The CMA1 levels were approximately double that found in the lung tissue of mild- chronic obstructive pulmonary disease patients and healthy individuals. CMA1 was found by the researchers to actively promote and progress the development of chronic obstructive pulmonary disease. Inhibiting the equivalent enzyme in mice was shown to provide protection in experimental models of chronic obstructive pulmonary disease. New drugs targeting CMA1.
Browse 26 Market Data Tables and 32 Figures spread through 178 Pages and in-depth TOC on “Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market”- Forecast to 2030, Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Drug Class (Bronchodilators (Beta 2-Agonists, Anticholinergics, Theophyllines), Phosphodiesterase Type 4 Inhibitors, Steroids, and Others), By Route of Administration (Oral and Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
Moreover, increasing adoption of inorganic strategies such as agreements by key players in market is expected to drive the global chronic obstructive pulmonary disease treatment market growth over the forecast period. For instance, in July 2022, Transpire Bio, a development-stage pharmaceutical company had signed an agreement with Recipharm AB, a pharmaceutical company to help with the development of TRB-1 and TRB-2. The agreement positions Transpire to tap into Recipharm’s experience of developing and manufacturing inhaled drug products as it seeks to advance its programs toward the clinic. Miami-based Transpire’s pipeline features a range of treatments for asthma and chronic obstructive pulmonary disease (COPD) based on dry powder, multi dose, and soft mist inhaler technologies.
Key Takeaways of the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market:
- Global chronic obstructive pulmonary disease (COPD) treatment market is expected to exhibit a CAGR of 4.9% during the forecast period due to increasing research and development activities for development of chronic obstructive pulmonary disease treatment. For instance, in March 2022, Pulmatrix, Inc., a pharmaceutical company, announced positive top-line results of its recently completed Phase Ib clinical study of PUR1800, a narrow-spectrum kinase inhibitor (NSKI) administered as a dry powder for inhalation with iSPERSE for evaluation in patients with stable Chronic Obstructive Pulmonary Disease (COPD). PUR1800 is being developed to treat Acute Exacerbations in Chronic Obstructive Pulmonary Disease (AECOPD). Initial safety and pharmacokinetics (PK) were evaluated in patients with stable COPD.
- Key Players are focused on improving existing treatment options, research and development for new treatments, and increasing approval from regulatory bodies, which is expected to aid the market growth over the forecast period. For instance, in June 2022, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies. A regulatory filing for this age group is under review by the European Medicines Agency and submissions to regulatory authorities in additional countries are advancing.
- Among regions, North America is estimated to account for the largest market share in the global chronic obstructive pulmonary disease (COPD) treatment market over the forecast period, owing to increasing prevalence of the chronic obstructive pulmonary disease in the region. For instance, in November 2019, according to the data published by the Center for Disease Control and Prevention, in the U.S., age-adjusted death rates for COPD were significantly lower in 2019 compared with 2017 among U.S. men (57.0 per 100,000 in 1999 and 40.5 per 100,000 in 2019) and among U.S. women (35.3 per 100,000 in 1999 and 34.3 per 100,000 in 2019). Blacks and American Indian/Alaska Natives have the highest current asthma rates compared to other races and ethnicities. In 2018, Blacks (10.9%) were 42 percent more likely than Whites (7.7%) to have asthma. According to World Health Organization, asthma affected an estimated 262 million people in 2019 (1) and caused 455, 000 deaths globally.
Major players operating in the global chronic obstructive pulmonary disease (COPD) treatment market include AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA.
